Finance Watch: Insilico Raises $255m To Take AI-Discovered Drugs Into The Clinic

Amplitude Closes CAD$200m ($162.3m) Precision Medicine Fund

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Private Company Edition: Nine new venture capital mega-rounds include Insilico’s series C, $250m from Blackstone for a CAR-T therapy spinout from Intellia and a $210m series B round for Umoja.

Finance Watch

Venture capital investors have not taken the summer off, at least not during the first few weeks of June, continuing to support mega-rounds of $100m or more for biopharmaceutical companies with novel therapeutics candidates and technology platforms, including a $255m series C round for the artificial intelligence-based drug discovery and development firm Insilico Medicine.

A frequent collaborator with big pharma partners, Insilico announced the super-sized venture capital round on 22 June and said the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.